摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1R,3aR,4S,7aR)-1-[(E,2R,3R)-3-ethenyl-6-(methoxymethoxy)-6-methylhept-4-en-2-yl]-7a-methyl-1,2,3,3a,4,5,6,7-octahydroinden-4-ol | 194158-84-4

中文名称
——
中文别名
——
英文名称
(1R,3aR,4S,7aR)-1-[(E,2R,3R)-3-ethenyl-6-(methoxymethoxy)-6-methylhept-4-en-2-yl]-7a-methyl-1,2,3,3a,4,5,6,7-octahydroinden-4-ol
英文别名
——
(1R,3aR,4S,7aR)-1-[(E,2R,3R)-3-ethenyl-6-(methoxymethoxy)-6-methylhept-4-en-2-yl]-7a-methyl-1,2,3,3a,4,5,6,7-octahydroinden-4-ol化学式
CAS
194158-84-4
化学式
C22H38O3
mdl
——
分子量
350.542
InChiKey
LZBODIXOECVHRI-JOGLFUNXSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5
  • 重原子数:
    25
  • 可旋转键数:
    8
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.82
  • 拓扑面积:
    38.7
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (1R,3aR,4S,7aR)-1-[(E,2R,3R)-3-ethenyl-6-(methoxymethoxy)-6-methylhept-4-en-2-yl]-7a-methyl-1,2,3,3a,4,5,6,7-octahydroinden-4-ol重铬酸吡啶4-甲基苯磺酸吡啶 作用下, 以 二氯甲烷 为溶剂, 反应 5.0h, 以94%的产率得到(1R,3aR,7aR)-1-[(E,2R,3R)-3-ethenyl-6-(methoxymethoxy)-6-methylhept-4-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-one
    参考文献:
    名称:
    A Short, Efficient Copper-Mediated Synthesis of 1α,25-Dihydroxyvitamin D2 (1α,25-Dihydroxyergocalciferol) and C-24 Analogs1,2
    摘要:
    Two synthetic routes to the nonnatural hormone 1 alpha,25-dihydroxyergocalciferol [2b, 1 alpha,25-(OH)(2)-D-2] and analogs modified at C-24 have been developed both starting from aldehyde 7b. Key steps in route A (eight steps, approximate to 38% overall yield from 7b) are (1) stereoselective addition of (E)-vinyllithium reagent 8c to aldehyde 7b; and (2) S(N)2' anti-displacement of the allylic phosphate of 5e by organocuprates derived from Grignard reagents and CuCN in the presence of LiCl. Key steps in route B (eight steps from 7b, 48% overall yield) are (1) Wittig-Horner type coupling between ketone 22, which bears an allylic phosphate group on the side chain, and the ylide derived from the Lythgoe-Roche phosphine oxide to form the vitamin D triene unit; and (2) efficient S(N)2' anti-displacement of the phosphate group of 23 by the organocuprate derived from MeMgCl, CuCN, and LiCl, without affecting the labile vitamin D triene system, to give, after deprotection, 1 alpha,25-(OH)2-D-2. Route B is particularly attractive as an approach to diverse C-24 vitamin D analogs for biological screening.
    DOI:
    10.1021/jo970604u
  • 作为产物:
    描述:
    tributyl-[3-(methoxymethoxy)-3-methylbut-1-enyl]stannane 在 正丁基锂四丁基氟化铵lithium chloride 作用下, 以 四氢呋喃 为溶剂, 反应 47.25h, 生成 (1R,3aR,4S,7aR)-1-[(E,2R,3R)-3-ethenyl-6-(methoxymethoxy)-6-methylhept-4-en-2-yl]-7a-methyl-1,2,3,3a,4,5,6,7-octahydroinden-4-ol
    参考文献:
    名称:
    A Short, Efficient Copper-Mediated Synthesis of 1α,25-Dihydroxyvitamin D2 (1α,25-Dihydroxyergocalciferol) and C-24 Analogs1,2
    摘要:
    Two synthetic routes to the nonnatural hormone 1 alpha,25-dihydroxyergocalciferol [2b, 1 alpha,25-(OH)(2)-D-2] and analogs modified at C-24 have been developed both starting from aldehyde 7b. Key steps in route A (eight steps, approximate to 38% overall yield from 7b) are (1) stereoselective addition of (E)-vinyllithium reagent 8c to aldehyde 7b; and (2) S(N)2' anti-displacement of the allylic phosphate of 5e by organocuprates derived from Grignard reagents and CuCN in the presence of LiCl. Key steps in route B (eight steps from 7b, 48% overall yield) are (1) Wittig-Horner type coupling between ketone 22, which bears an allylic phosphate group on the side chain, and the ylide derived from the Lythgoe-Roche phosphine oxide to form the vitamin D triene unit; and (2) efficient S(N)2' anti-displacement of the phosphate group of 23 by the organocuprate derived from MeMgCl, CuCN, and LiCl, without affecting the labile vitamin D triene system, to give, after deprotection, 1 alpha,25-(OH)2-D-2. Route B is particularly attractive as an approach to diverse C-24 vitamin D analogs for biological screening.
    DOI:
    10.1021/jo970604u
点击查看最新优质反应信息